1. Drugmakers are doing an inconsistent job of being transparent about how they release clinical trial data, even though about 95% have publicly accessible policies disclosing how they share this information. Many of the policies are vague. (Stat)
2. AstraZeneca’s share price fell 16% on Thursday after the drugmaker said that its Mystic clinical trial studying a combination of Imfinzi and tremelimumab did not meet its primary endpoint. (Reuters via the NYT)
3. Some mobile apps designed to target women trying to get pregnant or in the early days of their pregnancies reportedly shared email addresses and other information with marketers like Abbott. (Jezebel)
4. Procter & Gamble’s decision to cut more than $100 million in digital marketing spend had little impact on its business. The move is part of its strategy to stop spending on projects and campaigns that aren’t working. (WSJ)
5. ICYMI: An FDA advisory committee recommended against the regulator approving Intellipharmaceutics’ long-acting opioid painkiller, Rexista. The drug was developed as an abuse-deterrent version of Purdue Pharma’s OxyContin. (Reuters)
Correction: An earlier version of this article incorrectly cited the names of the drugs in the AstraZeneca trial. They are Imfinzi and tremelimumab.
